- The Pirola variant of SARS-CoV-2, discovered in 2023, exhibits unique characteristics, efficiently entering lung cells using the TMPRSS2 enzyme.
- Despite enhanced entry, it produces fewer infectious particles, limiting spread.
- The variant is resilient against therapeutic antibodies, emphasizing ongoing challenges in countering SARS-CoV-2 evolution.
A collaborative study conducted by researchers from the German Primate Center, Charité, Hannover Medical School, and Helmholtz Center investigates the biological properties of the Pirola variant, aiming to understand its impact on lung cells and immune responses.
Unique Entry Mechanism into Lung Cells
Contrary to previous Omicron variants, the Pirola variant exhibits high efficiency in entering lung cells, utilizing the TMPRSS2 enzyme. The study reveals key mutations in the spike protein influencing this efficient entry, resembling earlier variants like Alpha, Beta, Gamma, and Delta.
Reduced Viral Particle Production
While the Pirola variant demonstrates improved entry into lung cells, the researchers find a trade-off, as infected cells produce fewer new, infectious viral particles. This intriguing balance suggests potential limitations on the virus’s spread and pathogenicity despite enhanced cell entry.
Immune Evasion Strategies
The Pirola variant proves resistant to therapeutic antibodies and adept at evading antibody responses in both vaccinated and unvaccinated individuals. The study emphasizes the variant’s ability to resist existing antibody treatments, raising concerns about the ongoing adaptability of SARS-CoV-2.
Did you subscribe to our daily Newsletter?
It’s Free! Click here to Subscribe
Source: FAU
